title: Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
abstract: OBJECTIVE
  To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD).
  
  
  METHODS
  One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks.
  
  
  RESULTS
  After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
  
  
  CONCLUSIONS
  Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD.
authors.forename: Hui
authors.initials: H
authors.lastname: Fan
authors.forename: QingRong
authors.initials: Q
authors.lastname: Pan
authors.forename: Yuan
authors.initials: Y
authors.lastname: Xu
authors.forename: XinChun
authors.initials: X
authors.lastname: Yang
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D002097:C-Reactive Protein / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D005234:Fatty Liver / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D010455:Peptides / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*; D049629:Waist-Hip Ratio
chemical_list: D052242:Adiponectin; D000410:Alanine Transaminase; D001786:Blood Glucose; D002097:C-Reactive Protein; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D010455:Peptides; D014688:Venoms; C517652:hemoglobin A1c protein, human